Cheap levitra

Cheap levitra

A network of inexpensive seismometers, installed in people’s living cheap levitra rooms, gardens and workplaces across Haiti, is helping scientists to unravel the inner workings of the magnitude-7.2 earthquake that devastated the southwestern part of the Caribbean nation this month. The community-science effort launched after the country’s last major earthquake — a magnitude-7 tremor in 2010 that killed more than 100,000 people — and has since helped to reveal details about Haiti’s seismic activity. In a country whose official seismic-monitoring stations are sometimes offline because of limited resources, the community-seismology project provides much-needed data. Right now, the network is detecting aftershocks that continue to rattle cheap levitra the region. Its seismometers feed data into a system that displays the locations and magnitudes of Haitian earthquakes on a web-based portal in real time.

€œIt’s not professional equipment, and there are a lot of limitations,” says Dominique Boisson, a geologist at the State University of Haiti in Port-au-Prince who helps to run the network. But “some results cheap levitra are very nice”. Difficult work The network underscores just how far seismology in Haiti has come in 11 years. When the 2010 earthquake struck near Port-au-Prince, the country had no seismologists and just one official seismic-monitoring station, says Boisson. Now, there are several professional seismologists, as well cheap levitra as 7 stations in the official national network, which is operated by Haiti’s Bureau of Mines and Energy, and 15 in the community-science network.

Within days of the big quake hitting on 14 August, teams of scientists and technicians were driving towards its epicentre, carrying seismometers and other instruments to measure how the ground was moving. Monitoring the Earth with scientific instruments immediately after a quake allows researchers to better understand why the earthquake occurred and the future seismic risk. In 2010, it took weeks after the quake for foreign researchers to cheap levitra fly to Haiti and deploy instruments. This year, many of those foreign teams are forbidden to travel to Haiti because of erectile dysfunction treatment restrictions and political instability following the assassination in July of Haiti’s president, Jovenel Moïse. Instead, the work is being led by Haitian seismologists, such as Steeve Symithe, also at the State University, who, before he went into the field, was streaming Facebook Live presentations about the science of the quake to the Haitian public.

Both the 2010 and 2021 quakes happened in the Enriquillo–Plantain Garden fault zone, a cheap levitra tangle of fractures in Earth’s crust where the North American and Caribbean tectonic plates slide past one another. It runs from west to east along Haiti’s southern peninsula. The 2010 quake occurred on a previously unknown fault in that zone. The epicentre cheap levitra of the 2021 quake lies about 100 kilometres to the west, in the province of Nippes. At least 2,100 people died in the 14 August quake, although the total count has yet to be tallied.

The US Geological Survey estimates that there might have been more than 10,000 deaths. Many survivors endured heavy winds and rain from a tropical storm cheap levitra as they tried to shelter outside. The scientists en route to the area spent the night in their cars as rain pelted down, softening the ground and generating landslides as aftershocks shook the ground, Boisson tells Nature. €œIt was pretty difficult” for them, he says. DIY seismology The challenge of cheap levitra doing fieldwork in Haiti helped to inspire the creation of the community-seismology project in 2019.

That was when Eric Calais, a seismologist at the École Normale Supérieure in Paris who has studied Haiti’s earthquakes for years, happened across a company that sells seismic stations to hobbyists. Looking for ways around the national Haitian network’s intermittent data, he used leftover money from a grant to buy some stations. Known as Raspberry Shakes, they contain tiny accelerometers that detect when the ground trembles and send that information to be processed and commingled with that from other stations. These US$500 stations are not as cheap levitra sophisticated as Haiti’s official $50,000 monitoring stations. €œBut when it comes to locating quakes, determining magnitude, doing basic seismology — they are really excellent,” says Calais.

And because they are in people’s homes and workplaces, they more often have a steady supply of power and reliable Internet access. The team, which includes Calais, Boisson, Symithe and many cheap levitra others, recruited people to host the stations. Boisson had one in his garden until last week, when he dismantled it to move it closer to the epicentre of the 14 August quake. The host who had the Raspberry Shake closest to the epicentre was chagrined that his station was offline during the quake. He immediately ran out and topped up his Internet plan, says Calais, and the station cheap levitra was soon back up and running.

Funded by international supporters, Calais and his colleagues have kept the network of 15 stations operational for two years1. They aim to soon ramp up to 50 or more stations. Community-seismology networks have sprung up in other places around the world, but cheap levitra the Haiti network is unique in providing data in an area where few seismic data are otherwise collected, says Calais. The Haitian community-seismology data feed into a nationwide experimental system called Ayiti-Séismes, which is hosted at a website run by the Côte d’Azur University in Nice, France. Ayiti-Séismes also pulls data from official seismic stations in Haiti as well as those in nearby countries, including the Dominican Republic and Cuba.

The result is a real-time cheap levitra map of aftershocks blanketing southwestern Haiti in shades of red and orange. €œThe network is alive and well,” says Susan Hough, a seismologist at the US Geological Survey in Pasadena, California, who has worked in Haiti for many years, including after the 2010 quake. Future risk The quake’s epicentre is fairly close to quakes that occurred in 1952 and 1953, which were probably between magnitude 5 and 6, says Calais. In terms of future risk, the Enriquillo–Plantain Garden fault zone could still yield another major cheap levitra quake. €œIn this area, we cannot say that it’s over,” says Boisson.

Some speculate that the 2010 quake contributed to the recent one by transferring stress towards the region that just ruptured — and that seismic risk remains high in Port-au-Prince and across much of the Enriquillo–Plantain Garden fault zone. Boisson notes that many scientists have been worried about a different major geological region in Haiti’s north, known as the Septentrional cheap levitra fault zone. It unleashed a major quake in 1842. €œAfter 2010, we thought it would be this fault” that would cause future quakes, he says. €œAnd then it was in the south cheap levitra again.” About 600 aftershocks have been detected from the 14 August quake so far — compared with roughly 10 in the same time period after the 2010 quake, although there were undoubtedly more that were not detected, says Calais.

€œWe now have very strong information about not only where the [14 August] quake occurred, but also how wide the rupture was, in which direction the fault was dipping,” he adds. €œThat’s essential” to understanding why the quake occurred and what to expect in the future. This article is reproduced with permission and was first published on August 20 2021..

Levitra preiswert kaufen

Levitra
Viagra capsules
How fast does work
20mg 30 tablet $83.95
100mg 90 capsule $179.95
Effect on blood pressure
At walmart
Canadian Pharmacy
Pack price
4h
22h
Male dosage
50
43
How long does stay in your system
On the market
Order online
Buy with discover card
60mg 90 tablet $314.95
100mg 30 capsule $79.95
Average age to take
No
Yes

By regular https://www.mein2tes-leben.at/ mail levitra preiswert kaufen. You may mail written comments to the following address. CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention. Document Identifier/OMB Control levitra preiswert kaufen Number ___, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following. 1. Access CMS' website address at levitra preiswert kaufen https://www.cms.gov/​Regulations-and-Guidance/​Legislation/​PaperworkReductionActof1995/​PRA-Listing.html. 2.

Call the Reports Clearance Office at (410) 786-1326. Start Further levitra preiswert kaufen Info William N. Parham at (410) 786-4669. End Further Info End Preamble Start Supplemental Information Contents This notice sets out a summary of the use and burden associated with the following information collections.

More detailed information can be found in each collection's supporting statement and associated materials levitra preiswert kaufen (see ADDRESSES). CMS-10752 Submissions of 1135 Waiver Request Automated Process CMS-10137 Solicitation for Applications for Medicare Prescription Drug Plan 2022 Contracts CMS-R-262 CMS Plan Benefit Package (PBP) and Formulary CY 2022 CMS-10549 Generic Clearance. Questionnaire Testing and Methodological Research for the Medicare Current Beneficiary Survey (MCBS) Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information levitra preiswert kaufen they conduct or sponsor.

The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) levitra preiswert kaufen of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice.

Information Collection 1. Type of levitra preiswert kaufen Information Collection Request. Revision of a currently approved collection. Title of Information Collection.

Submissions of levitra preiswert kaufen 1135 Waiver Request Automated Process. Use. Waivers under Section 1135 of the Social Security Act (the Act) and certain flexibilities allow the CMS to relax certain requirements, known as the Conditions of Participation (CoPs) or Conditions of Coverage to promote the health and safety of beneficiaries. Under Section 1135 of the Act, the Secretary levitra preiswert kaufen may temporarily waive or modify certain Medicare, Medicaid, and Children's Health Insurance Program (CHIP) requirements to ensure that sufficient health care services are available to meet the needs of individuals enrolled in Social Security Act programs in the emergency area and time periods.

These waivers ensure that providers who provide such services in good faith can be reimbursed and exempted from sanctions. During emergencies, such as the current erectile dysfunction treatment public health emergency (PHE), CMS must be able to apply program waivers and flexibilities under section 1135 of the Social Security Act, in a timely manner to respond quickly to unfolding events. In a disaster or emergency, waivers and flexibilities assist health care providers/suppliers in providing timely healthcare and services to levitra preiswert kaufen people who have been affected and enables states, Federal districts, and U.S. Territories to ensure Medicare and/or Medicaid beneficiaries have continued access to care.

During disasters and emergencies, it is not uncommon to evacuate Medicare-participating facilities and relocate patients/residents to other provider settings or across state lines, especially, during hurricane and tornado events. CMS must collect relevant information for which a provider is requesting a waiver or flexibility to make proper decisions about levitra preiswert kaufen approving or denying such requests. Collection of this data aids in the prevention of gaps in access to care and services before, during, and after an emergency. CMS must also respond to inquiries related to a PHE from providers and beneficiaries.

CMS is levitra preiswert kaufen not collecting information from these inquiries. We are merely responding to them. Prior to this request, CMS did not have a standard process or OMB approval for providers/suppliers impacted to submit 1135 waiver/flexibility requests or inquiries, as these were generally seen on a smaller scale (natural disasters) prior to the erectile dysfunction treatment public health emergency. CMS has provided levitra preiswert kaufen general guidance to Medicare-participating facilities which can be viewed at https://www.cms.gov/​Medicare/​Provider-Enrollment-and-Certification/​SurveyCertEmergPrep/​1135-Waivers.

The requests and inquiries would be sent directly, via email, to the Survey Operations Group in each CMS Location (previously known as CMS Regional Offices) and the entity would provide a brief summary to CMS for a waiver/flexibility request or an answer to an inquiry. We are now developing a streamlined, automated process to standardize the 1135 waiver requests and inquiries submitted based on lessons learned during erectile dysfunction treatment PHE, primarily based on the volume of requests to ensure timely response to facility needs. The waiver request form was approved under an Emergency information collection levitra preiswert kaufen request on October 15, 2020. Furthermore, the normal operations of a healthcare provider are disrupted by emergencies or disasters occasionally.

When this occurs, State Survey Agencies (SA) deliver a provider/beneficiary tracking report regarding the current status of all affected healthcare providers and their beneficiaries. This report includes demographic information about the provider, their operational status, beneficiary status, and planned resumption levitra preiswert kaufen of normal operations. This information is provided whether or not a PHE has been declared. We are now developing a streamlined, automated process to standardize submission of this information directly by the provider during emergencies and eliminating the need for SA to provide it.

It will consist of a public facing web levitra preiswert kaufen form. This information will be used by CMS to receive, triage, respond to and report on requests and/or inquiries for Medicare, Medicaid, and CHIP beneficiaries. This information will be Start Printed Page 66992used to make decisions about approving or denying waiver and flexibility requests and may be used to identify trends that inform CMS Conditions for Coverage or Conditions for Participation policies during public health emergencies, when declared by the President and the HHS Secretary. Subsequent to the Emergency information collection request, we are revising the package to include a second form, Healthcare Facility Status Workflow, which is for operational levitra preiswert kaufen status information which will be used to assist providers in delivering critical care to beneficiaries during emergencies.

Form Number. CMS-10752 (OMB control number. 0938-1384). Frequency.

Occasionally. Affected Public. Private Sector. Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments.

Number of Respondents. 3,730. Total Annual Responses. 3,730.

Total Annual Hours. 3,730. (For policy questions regarding this collection, contact Adriane Saunders at 404-562-7484.) 2. Type of Information Collection Request.

Revision of a currently approved collection. Title of Information Collection. Solicitation for Applications for Medicare Prescription Drug Plan 2022 Contracts. Use.

Coverage for the prescription drug benefit is provided through contracted prescription drug plans (PDPs) or through Medicare Advantage (MA) plans that offer integrated prescription drug and health care coverage (MA-PD plans). Cost Plans that are regulated under Section 1876 of the Social Security Act, and Employer Group Waiver Plans (EGWP) may also provide a Part D benefit. Organizations wishing to provide services under the Prescription Drug Benefit Program must complete an application, negotiate rates, and receive final approval from CMS. Existing Part D Sponsors may also expand their contracted service area by completing the Service Area Expansion (SAE) application.

Collection of this information is mandated in Part D of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) in Subpart 3. The application requirements are codified in Subpart K of 42 CFR 423 entitled “Application Procedures and Contracts with PDP Sponsors.” The information will be collected under the solicitation of proposals from PDP, MA-PD, Cost Plan, Program of All Inclusive Care for the Elderly (PACE), and EGWP applicants. The collected information will be used by CMS to. (1) Ensure that applicants meet CMS requirements for offering Part D plans (including network adequacy, contracting requirements, and compliance program requirements, as described in the application), (2) support the determination of contract awards.

Form Number. CMS-10137 (OMB control number. 0938-0936). Frequency.

Yearly. Affected Public. Private Sector. Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments.

Number of Respondents. 658. Total Annual Responses. 331.

Total Annual Hours. 1,550. (For policy questions regarding this collection, contact Arianne Spaccarelli at 410-786-5715.) 3. Type of Information Collection Request.

Revision of a currently approved collection. Title of Information Collection. CMS Plan Benefit Package (PBP) and Formulary CY 2022. Use.

Under the Medicare Modernization Act (MMA), Medicare Advantage (MA) and Prescription Drug Plan (PDP) organizations are required to submit plan benefit packages for all Medicare beneficiaries residing in their service area. The plan benefit package submission consists of the Plan Benefit Package (PBP) software, formulary file, and supporting documentation, as necessary. MA and PDP organizations use the PBP software to describe their organization's plan benefit packages, including information on premiums, cost sharing, authorization rules, and supplemental benefits. They also generate a formulary to describe their list of drugs, including information on prior authorization, step cost of levitra at costco therapy, tiering, and quantity limits.

CMS requires that MA and PDP organizations submit a completed PBP and formulary as part of the annual bidding process. During this process, organizations prepare their proposed plan benefit packages for the upcoming contract year and submit them to CMS for review and approval. CMS uses this data to review and approve the benefit packages that the plans will offer to Medicare beneficiaries. This allows CMS to review the benefit packages in a consistent way across all submitted bids during with incredibly tight timeframes.

This data is also used to populate data on Medicare Plan Finder, which allows beneficiaries to access and compare Medicare Advantage and Prescription Drug plans. Form Number. CMS-R-262 (OMB control number. 0938-0763).

Frequency. Yearly. Affected Public. Private Sector.

Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments. Number of Respondents. 753. Total Annual Responses.

8,090. Total Annual Hours. 74,038. (For policy questions regarding this collection, contact Kristy Holtje at 410-786-2209.) 4.

Type of Information Collection Request. Revision of a currently approved collection. Title of Information Collection. Generic Clearance.

Questionnaire Testing and Methodological Research for the Medicare Current Beneficiary Survey (MCBS). Use. The current generic clearance for MCBS Questionnaire Testing and Methodological Research encompasses development and testing of MCBS questionnaires, instrumentation, and data collection protocols, as well as a mechanism for conducting methodological experiments. The current clearance includes conducting field tests and experiments, including split ballot experiments, within the MCBS production environment, and conducting usability tests.

The purpose of this OMB clearance package is to revise the current clearance to expand the methods to allow for field tests outside of MCBS production Field tests conducted within production do not incur any additional burden on respondents whereas tests conducted outside production must account for additional respondent burden. The MCBS is a continuous, multipurpose survey of a nationally representative sample of aged, disabled, and institutionalized Medicare beneficiaries. The MCBS, which is sponsored by the Centers for Medicare &. Medicaid Services (CMS), is the only comprehensive source of information on the health status, health care use and expenditures, health insurance coverage, and socioeconomic and demographic characteristics of the entire spectrum of Medicare beneficiaries.

The core of the MCBS is a series of interviews with a stratified random sample of the Medicare population, including aged and disabled enrollees, residing in the community or in institutions. Questions are asked about enrollees' patterns of health care use, charges, insurance coverage, and payments over time. Respondents are asked about their sources of health care coverage and payment, their demographic characteristics, their health and work history, and their family living circumstances. In addition to collecting information through the core questionnaire, the MCBS collects information on special topics.

Form Number. CMS-10549 (OMB control number. 0938-1275). Frequency.

Occasionally. Affected Public. Individuals or Households. Number of Respondents.

11,655. Total Annual Responses. 11,655. Total Annual Hours.

Start Printed Page 669933,947. (For policy questions regarding this collection, contact William Long at 410-786-7927.) Start Signature Dated. October 16, 2020. William N.

Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. End Signature End Supplemental Information [FR Doc. 2020-23335 Filed 10-20-20. 8:45 am]BILLING CODE 4120-01-PStart Preamble Start Printed Page 66989 Centers for Medicare &.

Medicaid Services (CMS), HHS. Final notice. This final notice announces our decision to approve The Joint Commission for continued recognition as a national accrediting organization for Ambulatory Surgical Centers that wish to participate in the Medicare or Medicaid programs. The decision announced in this notice is effective on December 20, 2020 through December 20, 2024.

Joy Webb (410) 786-1667. Erin Imhoff (410) 786-2337. I. Background Ambulatory Surgical Centers (ASCs) are distinct entities that operate exclusively for the purpose of furnishing outpatient surgical services to patients.

Under the Medicare program, eligible beneficiaries may receive covered services from an ASC provided certain requirements are met. Section 1832(a)(2)(F)(i) of the Social Security Act (the Act) establishes distinct criteria for a facility seeking designation as an ASC. Regulations concerning provider agreements are at 42 CFR part 489 and those pertaining to activities relating to the survey and certification of facilities are at 42 CFR part 488. The regulations at 42 CFR part 416 specify the conditions that an ASC must meet in order to participate in the Medicare program, the scope of covered services, and the conditions for Medicare payment for ASCs.

Generally, to enter into an agreement, an ASC must first be certified by a State survey agency (SA) as complying with the conditions or requirements set forth in part 416 of our Medicare regulations. Thereafter, the ASC is subject to regular surveys by an SA to determine whether it continues to meet these requirements. Section 1865(a)(1) of the Act provides that, if a provider entity demonstrates through accreditation by a Centers for Medicare &. Medicaid Services (CMS) approved national accrediting organization (AO) that all applicable Medicare conditions are met or exceeded, we may deem that provider entity as having met the requirements.

Accreditation by an AO is voluntary and is not required for Medicare participation. If an AO is recognized by the Secretary of the Department of Health and Human Services as having standards for accreditation that meet or exceed Medicare requirements, any provider entity accredited by the national accrediting body's approved program may be deemed to meet the Medicare conditions. The AO applying for approval of its accreditation program under part 488, subpart A, must provide CMS with reasonable assurance that the AO requires the accredited provider entities to meet requirements that are at least as stringent as the Medicare conditions. Our regulations concerning the approval of AOs are set forth at § 488.5.

The Joint Commission's (TJC's) current term of approval for its ASC program expires December 20, 2020. II. Application Approval Process Section 1865(a)(3)(A) of the Act provides a statutory timetable to ensure that our review of applications for CMS-approval of an accreditation program is conducted in a timely manner. The Act provides us 210 days after the date of receipt of a complete application, with any documentation necessary to make the determination, to complete our survey activities and application process.

Within 60 days after receiving a complete application, we must publish a notice in the Federal Register that identifies the national accrediting body making the request, describes the request, and provides no less than a 30-day public comment period. At the end of the 210-day period, we must publish a notice in the Federal Register approving or denying the application. III. Provisions of the Proposed Notice On May 26, 2020 we published a proposed notice in the Federal Register (85 FR 31511), announcing TJC's request for continued approval of its Medicare ASC accreditation program.

In the May 26, 2020 proposed notice, we detailed our evaluation criteria. Under section 1865(a)(2) of the Act and in our regulations at § 488.5, we conducted a review of TJC's Medicare ASC accreditation application in accordance with the criteria specified by our regulations, which include, but are not limited to the following. An administrative review of TJC's. (1) Corporate policies.

(2) financial and human resources available to accomplish the proposed surveys. (3) procedures for training, monitoring, and evaluation of its ASC surveyors. (4) ability to investigate and respond appropriately to complaints against accredited ASCs. And (5) survey review and decision-making process for accreditation.

The comparison of TJC's Medicare ASC accreditation program standards to our current Medicare ASC conditions for coverage (CfCs). A documentation review of TJC's survey process to do the following. ++ Determine the composition of the survey team, surveyor qualifications, and TJC's ability to provide continuing surveyor training. ++ Compare TJC's processes to those we require of state survey agencies, including periodic resurvey and the ability to investigate and respond appropriately to complaints against TJC-accredited ASCs.

++ Evaluate TJC's procedures for monitoring accredited ASCs it has found to be out of compliance with TJC's program requirements. (This pertains only to monitoring procedures when TJC identifies non-compliance. If noncompliance is identified by a SA through a validation survey, the SA monitors corrections as specified at § 488.9(c)). ++ Assess TJC's ability to report deficiencies to the surveyed ASCs and respond to the ASCs' plans of correction in a timely manner.

++ Establish TJC's ability to provide CMS with electronic data and reports necessary for effective validation and assessment of the organization's survey process. ++ Determine the adequacy of TJC's staff and other resources.

Territories to ensure Medicare and/or Medicaid beneficiaries have continued cheap levitra access to care. During disasters and emergencies, it is not uncommon to evacuate Medicare-participating facilities and relocate patients/residents to other provider settings or across state lines, especially, during hurricane and tornado events. CMS must collect relevant information for which a provider is requesting a waiver or flexibility to make proper decisions about approving or denying such requests. Collection of this data aids in the prevention cheap levitra of gaps in access to care and services before, during, and after an emergency. CMS must also respond to inquiries related to a PHE from providers and beneficiaries.

CMS is not collecting information from these inquiries. We are merely responding to cheap levitra them. Prior to this request, CMS did not have a standard process or OMB approval for providers/suppliers impacted to submit 1135 waiver/flexibility requests or inquiries, as these were generally seen on a smaller scale (natural disasters) prior to the erectile dysfunction treatment public health emergency. CMS has provided general guidance to Medicare-participating facilities which can be viewed at https://www.cms.gov/​Medicare/​Provider-Enrollment-and-Certification/​SurveyCertEmergPrep/​1135-Waivers. The requests and inquiries would be sent directly, via email, to the Survey Operations Group in each CMS Location (previously known as CMS Regional Offices) and the entity would provide a brief summary to CMS for a waiver/flexibility request or an answer to an cheap levitra inquiry.

We are now developing a streamlined, automated process to standardize the 1135 waiver requests and inquiries submitted based on lessons learned during erectile dysfunction treatment PHE, primarily based on the volume of requests to ensure timely response to facility needs. The waiver request form was approved under an Emergency information collection request on October 15, 2020. Furthermore, the normal operations of a healthcare provider are disrupted by emergencies or cheap levitra disasters occasionally. When this occurs, State Survey Agencies (SA) deliver a provider/beneficiary tracking report regarding the current status of all affected healthcare providers and their beneficiaries. This report includes demographic information about the provider, their operational status, beneficiary status, and planned resumption of normal operations.

This information is provided whether or not a PHE cheap levitra has been declared. We are now developing a streamlined, automated process to standardize submission of this information directly by the provider during emergencies and eliminating the need for SA to provide it. It will consist of a public facing web form. This information will be used by CMS to cheap levitra receive, triage, respond to and report on requests and/or inquiries for Medicare, Medicaid, and CHIP beneficiaries. This information will be Start Printed Page 66992used to make decisions about approving or denying waiver and flexibility requests and may be used to identify trends that inform CMS Conditions for Coverage or Conditions for Participation policies during public health emergencies, when declared by the President and the HHS Secretary.

Subsequent to the Emergency information collection request, we are revising the package to include a second form, Healthcare Facility Status Workflow, which is for operational status information which will be used to assist providers in delivering critical care to beneficiaries during emergencies. Form Number cheap levitra. CMS-10752 (OMB control number. 0938-1384). Frequency.

Occasionally. Affected Public. Private Sector. Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments. Number of Respondents.

3,730. Total Annual Responses. 3,730. Total Annual Hours. 3,730.

(For policy questions regarding this collection, contact Adriane Saunders at 404-562-7484.) 2. Type of Information Collection Request. Revision of a currently approved collection. Title of Information Collection. Solicitation for Applications for Medicare Prescription Drug Plan 2022 Contracts.

Use. Coverage for the prescription drug benefit is provided through contracted prescription drug plans (PDPs) or through Medicare Advantage (MA) plans that offer integrated prescription drug and health care coverage (MA-PD plans). Cost Plans that are regulated under Section 1876 of the Social Security Act, and Employer Group Waiver Plans (EGWP) may also provide a Part D benefit. Organizations wishing to provide services under the Prescription Drug Benefit Program must complete an application, negotiate rates, and receive final approval from CMS. Existing Part D Sponsors may also expand their contracted service area by completing the Service Area Expansion (SAE) application.

Collection of this information is mandated in Part D of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) in Subpart 3. The application requirements are codified in Subpart K of 42 CFR 423 entitled “Application Procedures and Contracts with PDP Sponsors.” The information will be collected under the solicitation of proposals from PDP, MA-PD, Cost Plan, Program of All Inclusive Care for the Elderly (PACE), and EGWP applicants. The collected information will be used by CMS to. (1) Ensure that applicants meet CMS requirements for offering Part D plans (including network adequacy, contracting requirements, and compliance program requirements, as described in the application), (2) support the determination of contract awards. Form Number.

CMS-10137 (OMB control number. 0938-0936). Frequency. Yearly. Affected Public.

Private Sector. Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments. Number of Respondents. 658. Total Annual Responses.

331. Total Annual Hours. 1,550. (For policy questions regarding this collection, contact Arianne Spaccarelli at 410-786-5715.) 3. Type of Information Collection Request.

Revision of a currently approved collection. Title of Information Collection. CMS Plan Benefit Package (PBP) and Formulary CY 2022. Use. Under the Medicare Modernization Act (MMA), Medicare Advantage (MA) and Prescription Drug Plan (PDP) organizations are required to submit plan benefit packages for all Medicare beneficiaries residing in their service area.

The plan benefit package submission consists of the Plan Benefit Package (PBP) software, formulary file, and supporting documentation, as necessary. MA and PDP organizations use the PBP software to describe their organization's plan benefit packages, including information on premiums, cost sharing, authorization rules, and supplemental benefits. They also generate a formulary to describe their list of drugs, including information on prior authorization, step therapy, tiering, and quantity limits. CMS requires that MA and PDP organizations submit a completed PBP and formulary as part of the annual bidding process. During this process, organizations prepare their proposed plan benefit packages for the upcoming contract year and submit them to CMS for review and approval.

CMS uses this data to review and approve the benefit packages that the plans will offer to Medicare beneficiaries. This allows CMS to review the benefit packages in a consistent way across all submitted bids during with incredibly tight timeframes. This data is also used to populate data on Medicare Plan Finder, which allows beneficiaries to access and compare Medicare Advantage and Prescription Drug plans. Form Number. CMS-R-262 (OMB control number.

0938-0763). Frequency. Yearly. Affected Public. Private Sector.

Business or other for-profits and Not-for-profit institutions and State, Local or Tribal Governments. Number of Respondents. 753. Total Annual Responses. 8,090.

Total Annual Hours. 74,038. (For policy questions regarding this collection, contact Kristy Holtje at 410-786-2209.) 4. Type of Information Collection Request. Revision of a currently approved collection.

Title of Information Collection. Generic Clearance. Questionnaire Testing and Methodological Research for the Medicare Current Beneficiary Survey (MCBS). Use. The current generic clearance for MCBS Questionnaire Testing and Methodological Research encompasses development and testing of MCBS questionnaires, instrumentation, and data collection protocols, as well as a mechanism for conducting methodological experiments.

The current clearance includes conducting field tests and experiments, including split ballot experiments, within the MCBS production environment, and conducting usability tests. The purpose of this OMB clearance package is to revise the current clearance to expand the methods to allow for field tests outside of MCBS production Field tests conducted within production do not incur any additional burden on respondents whereas tests conducted outside production must account for additional respondent burden. The MCBS is a continuous, multipurpose survey of a nationally representative sample of aged, disabled, and institutionalized Medicare beneficiaries. The MCBS, which is sponsored by the Centers for Medicare &. Medicaid Services (CMS), is the only comprehensive source of information on the health status, health care use and expenditures, health insurance coverage, and socioeconomic and demographic characteristics of the entire spectrum of Medicare beneficiaries.

The core of the MCBS is a series of interviews with a stratified random sample of the Medicare population, including aged and disabled enrollees, residing in the community or in institutions. Questions are asked about enrollees' patterns of health care use, charges, insurance coverage, and payments over time. Respondents are asked about their sources of health care coverage and payment, their demographic characteristics, their health and work history, and their family living circumstances. In addition to collecting information through the core questionnaire, the MCBS collects information on special topics. Form Number.

CMS-10549 (OMB control number. 0938-1275). Frequency. Occasionally. Affected Public.

Individuals or Households. Number of Respondents. 11,655. Total Annual Responses. 11,655.

Total Annual Hours. Start Printed Page 669933,947. (For policy questions regarding this collection, contact William Long at 410-786-7927.) Start Signature Dated. October 16, 2020. William N.

Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. End Signature End Supplemental Information [FR Doc. 2020-23335 Filed 10-20-20. 8:45 am]BILLING CODE 4120-01-PStart Preamble Start Printed Page 66989 Centers for Medicare &. Medicaid Services (CMS), HHS.

Final notice. This final notice announces our decision to approve The Joint Commission for continued recognition as a national accrediting organization for Ambulatory Surgical Centers that wish to participate in the Medicare or Medicaid programs. The decision announced in this notice is effective on December 20, 2020 through December 20, 2024. Joy Webb (410) 786-1667. Erin Imhoff (410) 786-2337.

I. Background Ambulatory Surgical Centers (ASCs) are distinct entities that operate exclusively for the purpose of furnishing outpatient surgical services to patients. Under the Medicare program, eligible beneficiaries may receive covered services from an ASC provided certain requirements are met. Section 1832(a)(2)(F)(i) of the Social Security Act (the Act) establishes distinct criteria for a facility seeking designation as an ASC. Regulations concerning provider agreements are at 42 CFR part 489 and those pertaining to activities relating to the survey and certification of facilities are at 42 CFR part 488.

The regulations at 42 CFR part 416 specify the conditions that an ASC must meet in order to participate in the Medicare program, the scope of covered services, and the conditions for Medicare payment for ASCs. Generally, to enter into an agreement, an ASC must first be certified by a State survey agency (SA) as complying with the conditions or requirements set forth in part 416 of our Medicare regulations. Thereafter, the ASC is subject to regular surveys by an SA to determine whether it continues to meet these requirements. Section 1865(a)(1) of the Act provides that, if a provider entity demonstrates through accreditation by a Centers for Medicare &. Medicaid Services (CMS) approved national accrediting organization (AO) that all applicable Medicare conditions are met or exceeded, we may deem that provider entity as having met the requirements.

Accreditation by an AO is voluntary and is not required for Medicare participation. If an AO is recognized by the Secretary of the Department of Health and Human Services as having standards for accreditation that meet or exceed Medicare requirements, any provider entity accredited by the national accrediting body's approved program may be deemed to meet the Medicare conditions. The AO applying for approval of its accreditation program under part 488, subpart A, must provide CMS with reasonable assurance that the AO requires the accredited provider entities to meet requirements that are at least as stringent as the Medicare conditions. Our regulations concerning the approval of AOs are set forth at § 488.5. The Joint Commission's (TJC's) current term of approval for its ASC program expires December 20, 2020.

II. Application Approval Process Section 1865(a)(3)(A) of the Act provides a statutory timetable to ensure that our review of applications for CMS-approval of an accreditation program is conducted in a timely manner. The Act provides us 210 days after the date of receipt of a complete application, with any documentation necessary to make the determination, to complete our survey activities and application process. Within 60 days after receiving a complete application, we must publish a notice in the Federal Register that identifies the national accrediting body making the request, describes the request, and provides no less than a 30-day public comment period. At the end of the 210-day period, we must publish a notice in the Federal Register approving or denying the application.

III. Provisions of the Proposed Notice On May 26, 2020 we published a proposed notice in the Federal Register (85 FR 31511), announcing TJC's request for continued approval of its Medicare ASC accreditation program. In the May 26, 2020 proposed notice, we detailed our evaluation criteria. Under section 1865(a)(2) of the Act and in our regulations at § 488.5, we conducted a review of TJC's Medicare ASC accreditation application in accordance with the criteria specified by our regulations, which include, but are not limited to the following. An administrative review of TJC's.

(1) Corporate policies. (2) financial and human resources available to accomplish the proposed surveys. (3) procedures for training, monitoring, and evaluation of its ASC surveyors. (4) ability to investigate and respond appropriately to complaints against accredited ASCs. And (5) survey review and decision-making process for accreditation.

The comparison of TJC's Medicare ASC accreditation program standards to our current Medicare ASC conditions for coverage (CfCs). A documentation review of TJC's survey process to do the following. ++ Determine the composition of the survey team, surveyor qualifications, and TJC's ability to provide continuing surveyor training. ++ Compare TJC's processes to those we require of state survey agencies, including periodic resurvey and the ability to investigate and respond appropriately to complaints against TJC-accredited ASCs. ++ Evaluate TJC's procedures for monitoring accredited ASCs it has found to be out of compliance with TJC's program requirements.

(This pertains only to monitoring procedures when TJC identifies non-compliance. If noncompliance is identified by a SA through a validation survey, the SA monitors corrections as specified at § 488.9(c)). ++ Assess TJC's ability to report deficiencies to the surveyed ASCs and respond to the ASCs' plans of correction in a timely manner. ++ Establish TJC's ability to provide CMS with electronic data and reports necessary for effective validation and assessment of the organization's survey process. ++ Determine the adequacy of TJC's staff and other resources.

++ Confirm TJC's ability to provide adequate funding for performing required surveys. ++ Confirm TJC's policies with respect to surveys being unannounced. ++ Confirm TJC's policies and procedures to avoid conflicts of interest, including the appearance of conflicts of interest, involving individuals who conduct surveys or participate in accreditation decisions. ++ Obtain TJC's agreement to provide CMS with a copy of the most current accreditation survey together with any other information related to the survey as we may require, including corrective action plans.Start Printed Page 66990 IV. Analysis of and Responses to Public Comments on the Proposed Notice In accordance with section 1865(a)(3)(A) of the Act, the May 26, 2020 proposed notice also solicited public comments regarding whether TJC's requirements met or exceeded the Medicare CfCs for ASCs.

No comments were received in response to our proposed notice. V. Provisions of the Final Notice A. Differences Between TJC's Standards and Requirements for Accreditation and Medicare Conditions and Survey Requirements We compared TJC's ASC accreditation requirements and survey process with the Medicare CfCs of parts 416, and the survey and certification process requirements of parts 488 and 489. Our review and evaluation of TJC's ASC application, which were conducted as described in section III of this final notice, yielded the following areas where, as of the date of this notice, TJC has completed revising its standards and certification processes in order to do all of the following.

Meet the standard's requirements of all of the following regulations. ++ Section 416.2, to include the regulatory definition of an ASC as a comparable TJC standard instead of a glossary definition. ++ Section 416.43(c)(2), to address the broad requirement under the quality improvement program to track adverse patient events. ++ Section 416.44(c), to include reference to the Health Care Facilities Code (HCFC) of the National Fire Protection Association (NFPA) 99 (2012 edition). ++ Section 416.45(a), to include adequate review of credential and personnel files during survey activity.

++ Section 416.48(a), to include policies regarding the administration of drugs be in accordance with acceptable standards of practice. ++ Section 416.50(a), to provide the correct regulatory citation reference to the CMS standard, “Condition for Coverage—Patient Rights. Notice of Rights.” ++ Section 488.5(a)(4)(iv), to include the requirement that all comparable Medicare CfC citations be included in the findings sections of TJC's survey reports. CMS also reviewed TJC's comparable survey processes, which were conducted as described in section III. Of this final notice, and yielded the following areas where, as of the date of this notice, TJC has completed revising its survey processes in order to demonstrate that it uses survey processes that are comparable to state survey agency processes by.

++ Modifying TJC's accreditation award letter to facilities to remove the term “lengthen” to eliminate potential conflict as it relates to survey cycle length not to exceed 36 months, as survey cycles for deeming purposes do not exceed this timeframe. ++ Adding references to the HCFC of the NFPA 99 (2012 edition). (NFPA 99) within its Accreditation Process and Surveyor Activity Guide. ++ Providing clarification to its Surveyor Activity Guide indicating that the 2012 edition of the NFPA Life Safety Code and NFPA 99 applies to ASCs, regardless of the number of patients served. ++ Clarifying the process for TJC's performance of on-site Evidence of Standard Compliance (ESC) processes, including what it means to provide coaching and guidance as part of TJC's ESC survey activities.

B. Term of Approval Based on our review described in section III. And section V. Of this final notice, we approve TJC as a national accreditation organization for ASCs that request participation in the Medicare program. The decision announced in this final notice is effective December 20, 2020 through December 20, 2024.

In accordance with § 488.5(e)(2)(i) the term of the approval will not exceed 6 years.

What should I watch for while taking Levitra?

If you notice any changes in your vision while taking this drug, notify your prescriber or health care professional as soon as possible. Stop using vardenafil right away if you have a loss of sight in one or both eyes. Contact your healthcare provider immediately. Contact your physician immediately if the erection lasts longer than 4 hours or if it becomes painful. This may be a sign of priapism and must be treated immediately to prevent permanent damage. If you experience symptoms of nausea, dizziness, chest pain or arm pain upon initiation of sexual activity after vardenafil use, you should refrain from further activity and should discuss the episode with your prescriber or health care professional as soon as possible. Do not change the dose of your medication. Please call your prescriber or health care professional to determine if your dose needs to be reevaluated. Using vardenafil does not protect you or your partner against HIV (the levitra that causes AIDS) or other sexually transmitted diseases.

Levitra discount prices

It is not known how levitra discount prices long antibodies to the erectile dysfunction levitra will remain present in your body after . It is not known whether having antibodies to the erectile dysfunction levitra will protect you from getting infected again or will help reduce how severe or how long a future erectile dysfunction treatment may be. Regardless of your test result, you must continue to follow public health guidelines to reduce the risk of . How levitra discount prices are people tested for erectile dysfunction treatment Two kinds of tests are currently available for erectile dysfunction treatment.

Tests for viral and antibody (serology) tests. A test for viral detects the levitra or a component of the levitra and tells you if you have a current erectile dysfunction treatment . This is done using a levitra discount prices swab from your nose or throat, or a saliva sample. An antibody (serology) test tells you if you, at some point, were exposed to the levitra and had a erectile dysfunction treatment .

This test is done using a sample of your blood. Serology tests aren't used to diagnose a current erectile dysfunction viral , since levitra discount prices they don't detect the levitra itself. A positive antibody (serology) test means that, at some point, you were infected by the erectile dysfunction levitra, the levitra that causes erectile dysfunction treatment. It can't tell how long ago you were infected or confirm that you are immune or protected from being reinfected.

What does it mean if you have a positive test result If you have a positive levitra discount prices serology test result, it is likely that you previously had a erectile dysfunction treatment and that you developed an antibody response to the levitra. Receiving a positive result indicates that you have been exposed to the levitra but does not necessarily mean that you are immune or protected from being reinfected. There is also a chance that this test can give a positive result that is wrong (a false positive result). Even a very precise antibody test may produce false positive levitra discount prices results on occasion.

If you have questions about the results of your antibody test, it is important to talk to your health care provider to help you understand. What does it mean if you have a negative test result If you have a negative serology test result, it likely means that antibodies to the levitra that causes erectile dysfunction treatment were not present in your sample. It is possible for this test to give a negative result that is wrong (a false negative result) even if you have previously levitra discount prices been infected with erectile dysfunction treatment. You may also have a negative test result because you were tested too early, before your body had time to produce antibodies.

If you have questions about the results of your antibody test, it is important to talk to your health care provider to help you understand. Follow public health advice to slow the spread of erectile dysfunction treatment Even if you have previously had a erectile dysfunction treatment , you must levitra discount prices still follow public health advice and take the same actions to prevent erectile dysfunction treatment as someone who has never had the . Wash your hands often with soap and water for at least 20 seconds. If soap and water aren’t available, use a hand sanitizer containing at least 60% alcohol.

Stay home as much as possible and if you need to leave the house, levitra discount prices practice physical distancing (approximately 2 m). Wear a non-medical mask or face covering to protect others when you can't maintain a 2 metre distance. Avoid close contact with people who are sick. Cough and sneeze into your sleeve and not your hands levitra discount prices.

Follow the advice of your local public health authority. Please contact your health care provider with any questions or concerns about your test. For more levitra discount prices information on erectile dysfunction treatment. 1-833-784-4397 Canada.ca/erectile dysfunctionOn this page Overview erectile dysfunction treatment is the infectious disease caused by erectile dysfunction, erectile dysfunction.

The World Health Organization (WHO) declared a global levitra related to erectile dysfunction treatment on March 11, 2020. The erectile dysfunction treatment levitra has created an unprecedented demand levitra discount prices and urgent need for access to medical devices. To respond to this urgent need, the Minister of Health signed the Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to erectile dysfunction treatment on March 30, 2020. The interim order (IO) helps address shortages of products related directly or indirectly to the erectile dysfunction treatment levitra.

It does this by providing an expedited process for levitra discount prices the importation and sale of such products including medical devices. Under the IO, medical devices that do not fully meet Canadian regulatory requirements are allowed to be imported into or manufactured for sale in Canada. Products that do not meet Canadian regulatory requirements but would be eligible for exceptional importation or sale may include. personal protective equipment (PPE) that does not have compliant labelling PPE that is labelled with the distributor’s contact information instead of the manufacturer’s contact information Class II to IV devices that are licensed in Canada but are being imported with labelling from levitra discount prices another jurisdiction products that have expired but show no signs of wear and whose expiration is not likely to impact safety Note.

The medical devices imported and sold under the IO are still subject to all of the regulatory requirements that pertain to. establishment licensing (sections 44 to 51.1 of the Medical Devices Regulations) distribution records (section 52) complaint handling (section 57) mandatory problem reporting (sections 59 to 62) recalls (sections 63 to 65.1) The applicable regulatory requirements are outlined in Health Canada’s guidance on medical device establishment licensing and fees. About the guidance document This guidance document is intended to help importers, distributors, manufacturers and other establishments meet their regulatory requirements, such as. It remains in effect as long as the IO is in effect.

They usually start to appear in your blood cheap levitra 7-10 days after your initial by the levitra. It is not known how long antibodies to the erectile dysfunction levitra will remain present in your body after . It is not known whether having antibodies to the erectile dysfunction levitra will protect you from getting infected again or will help reduce how severe or how long a future erectile dysfunction treatment may be. Regardless of your test result, you must continue to follow public health guidelines to reduce the cheap levitra risk of . How are people tested for erectile dysfunction treatment Two kinds of tests are currently available for erectile dysfunction treatment.

Tests for viral and antibody (serology) tests. A test for viral detects the levitra or a component of the levitra and tells you cheap levitra if you have a current erectile dysfunction treatment . This is done using a swab from your nose or throat, or a saliva sample. An antibody (serology) test tells you if you, at some point, were exposed to the levitra and had a erectile dysfunction treatment . This test cheap levitra is done using a sample of your blood.

Serology tests aren't used to diagnose a current erectile dysfunction viral , since they don't detect the levitra itself. A positive antibody (serology) test means that, at some point, you were infected by the erectile dysfunction levitra, the levitra that causes erectile dysfunction treatment. It can't tell how long ago you were infected or confirm that you are immune or protected from being cheap levitra reinfected. What does it mean if you have a positive test result If you have a positive serology test result, it is likely that you previously had a erectile dysfunction treatment and that you developed an antibody response to the levitra. Receiving a positive result indicates that you have been exposed to the levitra but does not necessarily mean that you are immune or protected from being reinfected.

There is also a chance that this test can give a positive result that is wrong (a false positive cheap levitra result). Even a very precise antibody test may produce false positive results on occasion. If you have questions about the results of your antibody test, it is important to talk to your health care provider to help you understand. What does it mean if you have a negative test result If you have a negative serology test result, it likely means that antibodies to the levitra that causes erectile dysfunction treatment were not present cheap levitra in your sample. It is possible for this test to give a negative result that is wrong (a false negative result) even if you have previously been infected with erectile dysfunction treatment.

You may also have a negative test result because you were tested too early, before your body had time to produce antibodies. If you have questions about the results of your antibody test, it is important to talk to your health care provider cheap levitra to help you understand. Follow public health advice to slow the spread of erectile dysfunction treatment Even if you have previously had a erectile dysfunction treatment , you must still follow public health advice and take the same actions to prevent erectile dysfunction treatment as someone who has never had the . Wash your hands often with soap and water for at least 20 seconds. If soap and water aren’t available, use a hand cheap levitra sanitizer containing at least 60% alcohol.

Stay home as much as possible and if you need to leave the house, practice physical distancing (approximately 2 m). Wear a non-medical mask or face covering to protect others when you can't maintain a 2 metre distance. Avoid close contact with people who are cheap levitra sick. Cough and sneeze into your sleeve and not your hands. Follow the advice of your local public health authority.

Please contact your health care provider cheap levitra with any questions or concerns about your test. For more information on erectile dysfunction treatment. 1-833-784-4397 Canada.ca/erectile dysfunctionOn this page Overview erectile dysfunction treatment is the infectious disease caused by erectile dysfunction, erectile dysfunction. The World Health cheap levitra Organization (WHO) declared a global levitra related to erectile dysfunction treatment on March 11, 2020. The erectile dysfunction treatment levitra has created an unprecedented demand and urgent need for access to medical devices.

To respond to this urgent need, the Minister of Health signed the Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to erectile dysfunction treatment on March 30, 2020. The interim order (IO) cheap levitra helps address shortages of products related directly or indirectly to the erectile dysfunction treatment levitra. It does this by providing an expedited process for the importation and sale of such products including medical devices. Under the IO, medical devices that do not fully meet Canadian regulatory requirements are allowed to be imported into or manufactured for sale in Canada. Products that do not meet Canadian regulatory requirements but would cheap levitra be eligible for exceptional importation or sale may include.

personal protective equipment (PPE) that does not have compliant labelling PPE that is labelled with the distributor’s contact information instead of the manufacturer’s contact information Class II to IV devices that are licensed in Canada but are being imported with labelling from another jurisdiction products that have expired but show no signs of wear and whose expiration is not likely to impact safety Note. The medical devices imported and sold under the IO are still subject to all of the regulatory requirements that pertain to. establishment licensing (sections 44 to 51.1 of the Medical Devices Regulations) distribution records (section 52) complaint handling (section 57) mandatory problem reporting (sections 59 to 62) recalls (sections 63 to 65.1) The applicable regulatory requirements are outlined in Health Canada’s guidance on medical device establishment licensing and fees. About the guidance document This guidance document is intended to help importers, distributors, manufacturers and other establishments meet their regulatory requirements, such as. It remains in effect as long as the IO is in effect.

Dr jason levitre fort lauderdale

Abemaciclib 215268 dr jason levitre fort lauderdale Verzenio Eli Your Domain Name Lilly Canada Inc. N/A 2019-04-08 2025-04-08 N/A 2027-04-08 acalabrutinib 214504 Calquence AstraZeneca Canada Inc. N/A 2019-08-23 dr jason levitre fort lauderdale 2025-08-23 N/A 2027-08-23 aclidinium bromide 157598 Tudorza Genuair AstraZeneca Canada Inc. Duaklir Genuair 2013-07-29 2019-07-29 N/A 2021-07-29 afatinib dimaleate 158730 Giotrif Boehringer Ingelheim (Canada) Ltd.

N/A 2013-11-01 2019-11-01 N/A 2021-11-01 aflibercept 149321 Eylea Bayer Inc. N/A 2013-11-08 2019-11-08 N/A 2021-11-08 albiglutide dr jason levitre fort lauderdale 165145 Eperzan GlaxoSmithKline Inc. N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc.

KazanoOseni 2013-11-27 2019-11-27 dr jason levitre fort lauderdale N/A 2021-11-27 alpelisib 226941 Piqray Novartis Pharmaceuticals Canada Inc. N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine (supplied as amifampridine phosphate) 232685 Firdapse Kye Pharmaceuticals Inc. N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 dr jason levitre fort lauderdale antihemophilic factor (recombinant BDD), Fc fusion protein 163447 Eloctate Sanofi-Aventis Canada Inc.

N/A 2014-08-22 2020-08-22 Yes 2023-02-22 antihemophilic factor (recombinant), pegylated 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 dr jason levitre fort lauderdale Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla CSL Behring Canada Inc. N/A 2016-12-12 2022-12-12 Yes 2025-06-12 anthrax antigen fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc.

N/A 2019-07-04 dr jason levitre fort lauderdale 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada Janssen Inc. N/A 2018-07-03 2024-07-03 N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc. N/A 2014-11-12 2020-11-12 N/A 2022-11-12 asfotase alfa 179340 Strensiq Alexion Pharma International Sàrl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A dr jason levitre fort lauderdale 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 Olumiant Eli Lilly Canada Inc.

N/A 2018-08-17 2024-08-17 N/A 2026-08-17 bazedoxifene acetate 160681 Duavive Pfizer Canada Inc. N/A 2014-10-23 2020-10-23 N/A 2022-10-23 benralizumab 204008 Fasenra AstraZeneca Canada Inc. N/A 2018-02-22 2024-02-22 Yes 2026-08-22 bepotastine besilate 179294 Bepreve Bausch and Lomb Incorporated N/A 2016-07-27 2022-07-27 Yes 2025-01-27 bictegravir dr jason levitre fort lauderdale 203718 Biktarvy Gilead Sciences Canada, Inc. N/A 2018-07-10 2024-07-10 Yes 2027-01-10 bilastine 184231 Blexten Aralez Pharmaceutials Canada Inc.

N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 Mektovi Pfizer dr jason levitre fort lauderdale Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer Canada Inc. N/A 2014-03-07 2020-03-07 N/A 2022-03-07 botulism antitoxin heptavalen C/ D/ F/ G - (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co. Ltd.

N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc. N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A 2028-03-12 bromfenac sodium sesquihydrate 171657 Prolensa Bausch &.

Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc. N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A 2022-05-23 caplacizumab 230001 Cablivi Sanofi-Aventis Canada Inc. N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc.

N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 2026-07-07 N/A 2028-07-07 ceftolozane 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc. N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate Dompé farmaceutici S.p.A.

N/A 2019-02-08 2025-02-08 N/A 2027-02-08 ceritinib 175702 Zykadia Novartis Pharmaceuticals Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc. N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc fusion protein 163614 Alprolix Sanofi-Aventis Canada Inc.

N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc. N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 dabrafenib mesylate 157590 Tafinlar Novartis Pharmaceuticals Canada Inc. N/A 2013-07-16 2019-07-16 N/A 2021-07-16 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc.

N/A 2016-12-08 2022-12-08 N/A 2024-12-08 dacomitinib 214572 Vizimpro Pfizer Canada Inc. N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc. N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc. XigduoQtern 2014-12-12 2020-12-12 N/A 2022-12-12 daratumumab 187648 Darzalex Janssen Inc.

Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp. N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc. N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc.

N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc. Delstrigo 2018-10-12 2024-10-12 N/A 2026-10-12 dulaglutide 168671 Trulicity Eli Lilly Canada Inc. N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc.

N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban 187363 Lixiana Servier Canada Inc. N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc. N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin International Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc.

N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd. SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc. N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 eptinezumab 233288 Vyepti Lundbeck Canada Inc. N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc.

N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc. N/A 2018-08-01 2024-08-01 N/A 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc. SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 Nextstellis Searchlight Pharma Inc.

N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc. N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell Medical Inc. N/A 2021-04-22 2027-04-22 Yes 2029-10-22 finafloxacin 172450 Xtoro MerLion Pharmaceuticals GmbH N/A 2016-03-11 2022-03-11 Yes 2024-09-11 flibanserin 189352 Addyi Searchlight Pharma Inc.

N/A 2018-02-27 2024-02-27 N/A 2026-02-27 florbetaben (18F) 193105 Neuraceq Isologic Innovative Radiopharmaceuticals Ltd. N/A 2017-02-22 2023-02-22 N/A 2025-02-22 follitropin delta 188743 Rekovelle Ferring Inc. N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc. N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc.

N/A 2019-07-30 2025-07-30 N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin Pharmaceutical Inc. N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc. N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd.

N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc. N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes 2022-01-05 guselkumab 200590 Tremfya Janssen Inc. N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc.

N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 icatibant acetate 162918 Firazyr Takeda Canada Inc. N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc. N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc.

N/A 2021-05-26 2027-05-26 N/A 2029-05-26 idelalisib 172652 Zydelig Gilead Sciences Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 Besponsa Pfizer Canada Inc. N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc.

Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc. N/A 2017-12-07 2023-12-07 N/A 2025-12-07 iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc. N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc.

N/A 2016-12-23 2022-12-23 Yes 2025-06-23 ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc. N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc. N/A 2016-05-25 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda Canada Inc.

N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc. N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &. Lomb Incorporated N/A 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc. N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc.

N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc. N/A 2017-11-01 2023-11-01 N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc. N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc. N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc.

N/A 2013-12-02 2019-12-02 N/A 2021-12-02 lixisenatide 193862 Adlyxine Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd. N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc. N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu oxodotreotide 217184 Lutathera Advanced Accelerator Applications USA, Inc.

N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc. N/A 2013-11-06 2019-11-06 Yes 2022-05-06 mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada Inc. N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc.

N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A 2025-09-05 modified vaccinia levitra (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight Therapeutics Inc. N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc. N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily B 195550 Trumenba Pfizer Canada Inc.

N/A 2017-10-05 buy levitra with paypal 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc. N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc. N/A 2019-06-27 2025-06-27 N/A 2027-06-27 nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc. N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc.

N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc. N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 Jetrea ThromboGenics N.V. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc.

N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc. N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc. N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin 192925 Ozanex Ferrer Internacional, S.A.

N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc. Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V.

N/A 2019-06-07 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc. N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc. N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant hydrochloride 238175 Wakik Endo Ventures Ltd.

N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc. N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc. N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc.

N/A 2018-10-26 2024-10-26 N/A 2026-10-26 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A 2027-11-01 ponatinib hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc. N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc. N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc.

N/A 2017-01-05 2023-01-05 Yes 2025-07-05 radium - 223 dichloride 161312 Xofigo Bayer Inc. N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc. N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomalevitra types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc. N/A 2015-02-05 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc.

N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc. N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 remdesivir 240551 Veklury Gilead Sciences Canada, Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 reslizumab 185873 Cinqair Teva Canada Limited N/A 2016-07-20 2022-07-20 Yes 2025-01-20 ribociclib (supplied as ribociclib succinate) 203884 Kisqali Novartis Pharmaceuticals Canada Inc.

N/A 2018-03-02 2024-03-02 N/A 2026-03-02 rifaximin 161256 Zaxine Salix Pharmaceuticals Inc. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 riociguat 162761 Adempas Bayer Inc. N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc. N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen Canada Inc.

N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc. N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc. N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide mesylate) 207115 Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc.

N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc. N/A 2015-02-27 2021-02-27 Yes 2023-08-27 selexipag 182114 Uptravi Janssen Inc. N/A 2016-01-20 2022-01-20 N/A 2024-01-20 semaglutide 202059 Ozempic Novo Nordisk Canada Inc. Rybelsus 2018-01-04 2024-01-04 N/A 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc.

N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc. N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 Sovaldi Gilead Sciences Canada Inc. HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd.

N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck Canada Inc. N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc. N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC N/A 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc.

N/A 2014-05-29 2020-05-29 Yes 2022-11-29 tedizolid phosphate 173603 Sivextro Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc. N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc. N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc.

N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc. DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc. N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc.

N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 Xeljanz Pfizer Canada Inc. N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc. N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc. N/A 2021-04-15 2027-04-15 N/A 2029-04-15 trastuzumab emtansine 162414 Kadcyla Hoffmann-La Roche Limited N/A 2013-09-11 2019-09-11 N/A 2021-09-11 trifarotene 221945 Aklief Galderma Canada Inc.

N/A 2019-11-25 2025-11-25 Yes 2028-05-25 tipiracil hydrochloride 205852 Lonsurf Taiho Pharma Canada Inc. N/A 2018-01-25 2024-01-25 N/A 2026-01-25 triheptanoin 242196 Dojolvi Uagenyx Pharmaceutical Inc. N/A 2021-02-15 2027-02-15 Yes 2029-08-15 tucatinib 235295 Tukysa Seattle Genetics Inc. N/A 2020-06-05 2026-06-05 N/A 2028-06-05 turoctocog alfa 170796 Zonovate Novo Nordisk Canada Inc.

N/A 2014-12-08 2020-12-08 Yes 2023-06-08 umeclidinium bromide 161585 Anoro Ellipta GlaxoSmithKline Inc. Incruse Ellipta 2013-12-23 2019-12-23 N/A 2021-12-23 upadacitinib 223734 Rinvoq AbbVie Corporation N/A 2019-12-23 2025-12-23 N/A 2027-12-23 varicella-zoster levitra glycoprotein E (gE) 200244 Shingrix GlaxoSmithKline Inc. N/A 2017-10-13 2023-10-13 N/A 2025-10-13 vedolizumab 169414 Entyvio Takeda Canada Inc. N/A 2015-01-29 2021-01-29 Yes 2023-07-29 velpatasvir 190521 Epclusa Gilead Sciences Canada Inc.

Vosevi 2016-07-11 2022-07-11 Yes 2025-01-11 venetoclax 190761 Venclexta AbbVie Corporation N/A 2016-09-30 2022-09-30 N/A 2024-09-30 vernakalant hydrochloride 190817 Brinavess Cipher Pharmaceuticals Inc. N/A 2017-03-13 2023-03-13 N/A 2025-03-13 vilanterol trifenatate 157301 Breo Ellipta GlaxoSmithKline Inc. Anoro ElliptaTrelegy Ellipta 2013-07-03 2019-07-03 Yes 2022-01-03 vilazodone hydrochloride 176820 Viibryd Allergan Inc. N/A 2015-07-16 2021-07-16 Yes 2024-01-16 vismodegib 154608 Erivedge Hoffmann-La Roche Ltd.

N/A 2013-07-12 2019-07-12 N/A 2021-07-12 von willebrand factor (recombinant) (vonicog alfa) 213188 Vonvendi Takeda Canada Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 vorapaxar sulfate 179320 Zontivity Toprol Acquisition LLC N/A 2016-05-13 2022-05-13 N/A 2024-05-13 voretigene neparvovec 233097 Luxturna Novartis Pharmaceuticals Canada Inc. N/A 2020-10-13 2026-10-13 Yes 2029-04-13 vortioxetine hydrobromide 159019 Trintellix Lundbeck Canada Inc. N/A 2014-10-22 2020-10-22 Yes 2023-04-22 voxilaprevir 202324 Vosevi Gilead Sciences Canada Inc.

N/A 2017-08-16 2023-08-16 N/A 2025-08-16 zanubrutinib 242748 Brukinsa BeiGene Switzerland GmbH N/A 2021-03-01 2027-03-01 N/A 2029-03-01What is the Notice of Compliance (NOC) Data Extract?. The data extract is a series of compressed ASCII text files of the database. The uncompressed size of the files is approximately 22.7 MB. In order to utilize the data, the file must be loaded into an existing database or information system.

The typical user is most likely a third party claims adjudicator, provincial formulary, insurance company, etc. A casual user of this file must be familiar with database structure and capable of setting up queries. The "Read me" file contains the data structure required to download the zipped files.The NOC extract files have been updated. They contain Health Canada authorization dates for all drugs dating back to 1994 that have received an NOC.

All NOCs issued between 1991 and 1993 can be found in the NOC listings.Please note any Portable Document Format (PDF) files visible on the NOC database are not part of the data extracts.For more information, please go to the Read Me File.Data Extracts - Last updated. 2021-06-25 CopyrightFor information on copyright and who to contact, please visit the Notice of Compliance Online Database Terms and Conditions.The first WHO World Local Production Forum ended today after five days of discussions centered on promoting quality and sustainable local production to improve access to medicines and other health technologies.Delegates from over 100 countries, international partners, civil society groups, industry associations, and major investors joined WHO, WTO, UNIDO, UNICEF and UNCTAD to highlight the challenges facing local production and the steps required to address them, as well as the range of opportunities for the sector. Looking ahead, the Forum will provide a platform to drive forward efforts to support and enhance local production of health products in low- and middle-income countries. Forum conclusions, recommendations and next stepsIncreasing manufacturing capacity for global security - The erectile dysfunction treatment levitra has highlighted the importance of local manufacturing as a key component of levitra response by reducing reliance on global markets and imported products.

treatment production was a central theme at the Forum, as were the role of new technologies and generation of flexible manufacturing strategies to develop sustained production capacity in low- and middle-income countries. Technology transfer and licensing were seen as key to scaling up production. Sharing intellectual property and know-how will be essential, along with facilitation of voluntary licensing and effective technology transfer. It will also be vital to create a favourable environment for technology transfer.

Key elements will include good governance. A skilled workforce. Good access to market information and careful assessment of local capacity to receive and absorb the transferred technology.Governments’ role is key in creating an enabling political environment and a supportive business eco-system. Such efforts must be coordinated with relevant stakeholders at national, regional and global levels.

National regulators and local manufacturers can drive quality-compliant local production and facilitate faster access to health technologies during levitras and beyond. To do that, they need continued training, support and resources.Low access to capital is a key limiting factor for local manufacturers in low- and middle-income countries. The greater interest expressed by key development banks and other financial institutions towards investing in the sector indicates improvement in this area, whilst the need to develop strong investment cases, including demonstration of a long term economically viable business case, were highlighted as key components of successful manufacturing projects.A mechanism to stimulate industry engagement was recommended for strengthened collaboration with and among industry bodies with the aim of transferring priority technologies to low- and middle-income countries. A strategic advisory group should be established by WHO in collaboration with Member States and partners to address current and future global challenges and trends in local production and technology transfer.The next Forum will be held in The Netherlands as announced by Deputy Prime Minister and Minister of Health, Welfare and Sport, Hugo De Jonge.

The Local Production Forum is now established as a long-term mechanism to promote dialogue and decision-making to strengthen local manufacturing capacity and move towards the shared goal of universal access to health technologies.On June 15, 2021, we, the Directors General of WHO, WIPO and the WTO, met in a spirit of cooperation and solidarity to map out further collaboration to tackle the erectile dysfunction treatment levitra and the pressing global challenges at the intersection of public health, intellectual property and trade. Acutely conscious of our shared responsibility to communities across the world as they confront a health crisis of unprecedented severity and scale, we pledged to bring the full extent of the expertise and resources of our respective institutions to bear in ending the erectile dysfunction treatment levitra and improving the health and well-being of all people, everywhere around the globe. We underscored our commitment to universal, equitable access to erectile dysfunction treatments, therapeutics, diagnostics, and other health technologies – a commitment anchored in the understanding that this is an urgent moral imperative in need of immediate practical action. In this spirit, we agreed to build further on our long-standing commitment to WHO-WIPO-WTO Trilateral Cooperation that aims to support and assist all countries as they seek to assess and implement sustainable and integrated solutions to public health challenges.

Within this existing cooperative framework, we agreed to enhance and focus our support in the context of the levitra through two specific initiatives.First, our three agencies will collaborate on the organization of practical, capacity-building workshops to enhance the flow of updated information on current developments in the levitra and responses to achieve equitable access to erectile dysfunction treatment health technologies. The aim of these workshops is to strengthen the capacity of policymakers and experts in member governments to address the levitra accordingly. The first workshop in the series will be a workshop on technology transfer and licensing, scheduled for September. The workshop will help our members update their knowledge and understanding of how intellectual property, know-how and technology transfer work in actuality.

This would be in the context of medical technologies and related products and services. This first workshop will be followed by others on related practical themes. Secondly, we will implement a joint platform for tripartite technical assistance to countries relating to their needs for erectile dysfunction treatment medical technologies, providing a one-stop shop that will make available the full range of expertise on access, IP and trade matters provided by our organizations, and other partners, in a coordinated and systematic manner. The platform for technical assistance will, in particular, support countries to assess and prioritize unmet needs for erectile dysfunction treatments, medicines and related technologies, and provide timely and tailored technical assistance in making full use of all available options to access treatments, medicines and technologies, including through coordination between members facing similar challenges to facilitate collective responses.These initiatives will also be underpinned by our joint efforts to collect and make accessible robust and inclusive data needed to guide an effective response to the erectile dysfunction treatment levitra.

This will include a periodical update of the overview of erectile dysfunction treatment 19-related measures that are mapped in a key resource for trilateral cooperation, the WHO-WIPO-WTO publication 'Promoting Access to Medical Technologies and Innovation. Intersections between public health, intellectual property and trade', published in 2020.BackgroundThe World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) have, since 2009, stepped up their cooperation and practical coordination on issues relating to public health, IP and trade. This trilateral cooperation is intended to enhance the empirical and factual information basis for policy makers and to support them in addressing public health in relation to IP and trade. It has entailed a series of practical technical assistance activities, at the national, regional and mulitilateral levels, a series of high-level Policy Symposia intended to track emerging issues and inform future policy, and the trilateral study, which provides a comprehensive overview of the full array of policy issues with bearing on innovation and access to medical technologies..

Abemaciclib 215268 Verzenio http://www.hund-entwurmen.de/ Eli Lilly Canada Inc cheap levitra. N/A 2019-04-08 2025-04-08 N/A 2027-04-08 acalabrutinib 214504 Calquence AstraZeneca Canada Inc. N/A 2019-08-23 2025-08-23 N/A 2027-08-23 aclidinium cheap levitra bromide 157598 Tudorza Genuair AstraZeneca Canada Inc. Duaklir Genuair 2013-07-29 2019-07-29 N/A 2021-07-29 afatinib dimaleate 158730 Giotrif Boehringer Ingelheim (Canada) Ltd. N/A 2013-11-01 2019-11-01 N/A 2021-11-01 aflibercept 149321 Eylea Bayer Inc.

N/A 2013-11-08 2019-11-08 N/A 2021-11-08 albiglutide 165145 cheap levitra Eperzan GlaxoSmithKline Inc. N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc. KazanoOseni 2013-11-27 2019-11-27 cheap levitra N/A 2021-11-27 alpelisib 226941 Piqray Novartis Pharmaceuticals Canada Inc. N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine (supplied as amifampridine phosphate) 232685 Firdapse Kye Pharmaceuticals Inc.

N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 cheap levitra Yes 2026-05-06 antihemophilic factor (recombinant BDD), Fc fusion protein 163447 Eloctate Sanofi-Aventis Canada Inc. N/A 2014-08-22 2020-08-22 Yes 2023-02-22 antihemophilic factor (recombinant), pegylated 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) cheap levitra (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla CSL Behring Canada Inc.

N/A 2016-12-12 2022-12-12 Yes 2025-06-12 anthrax antigen fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc. N/A 2019-07-04 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada cheap levitra Janssen Inc. N/A 2018-07-03 2024-07-03 N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc. N/A 2014-11-12 2020-11-12 N/A 2022-11-12 asfotase alfa 179340 Strensiq Alexion Pharma International Sàrl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 cheap levitra Olumiant Eli Lilly Canada Inc.

N/A 2018-08-17 2024-08-17 N/A 2026-08-17 bazedoxifene acetate 160681 Duavive Pfizer Canada Inc. N/A 2014-10-23 2020-10-23 N/A 2022-10-23 benralizumab 204008 Fasenra AstraZeneca Canada Inc. N/A 2018-02-22 2024-02-22 Yes 2026-08-22 bepotastine besilate 179294 Bepreve Bausch and Lomb Incorporated N/A 2016-07-27 2022-07-27 Yes 2025-01-27 bictegravir 203718 cheap levitra Biktarvy Gilead Sciences Canada, Inc. N/A 2018-07-10 2024-07-10 Yes 2027-01-10 bilastine 184231 Blexten Aralez Pharmaceutials Canada Inc. N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 Mektovi Pfizer Canada cheap levitra ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer Canada Inc.

N/A 2014-03-07 2020-03-07 N/A 2022-03-07 botulism antitoxin heptavalen C/ D/ F/ G - (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co. Ltd. N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc.

N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A 2028-03-12 bromfenac sodium sesquihydrate 171657 Prolensa Bausch &. Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc. N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A 2022-05-23 caplacizumab 230001 Cablivi Sanofi-Aventis Canada Inc.

N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc. N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 2026-07-07 N/A 2028-07-07 ceftolozane 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc. N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate Dompé farmaceutici S.p.A.

N/A 2019-02-08 2025-02-08 N/A 2027-02-08 ceritinib 175702 Zykadia Novartis Pharmaceuticals Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc. N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc fusion protein 163614 Alprolix Sanofi-Aventis Canada Inc. N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc.

N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 dabrafenib mesylate 157590 Tafinlar Novartis Pharmaceuticals Canada Inc. N/A 2013-07-16 2019-07-16 N/A 2021-07-16 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc. N/A 2016-12-08 2022-12-08 N/A 2024-12-08 dacomitinib 214572 Vizimpro Pfizer Canada Inc. N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc.

N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc. XigduoQtern 2014-12-12 2020-12-12 N/A 2022-12-12 daratumumab 187648 Darzalex Janssen Inc. Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp. N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc.

N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc. N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc. Delstrigo 2018-10-12 2024-10-12 N/A 2026-10-12 dulaglutide 168671 Trulicity Eli Lilly Canada Inc. N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc.

N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban 187363 Lixiana Servier Canada Inc. N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc. N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin International Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc. N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd.

SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc. N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 eptinezumab 233288 Vyepti Lundbeck Canada Inc. N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc. N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc. N/A 2018-08-01 2024-08-01 N/A 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc.

SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 Nextstellis Searchlight Pharma Inc. N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc. N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell Medical Inc.

N/A 2021-04-22 2027-04-22 Yes 2029-10-22 finafloxacin 172450 Xtoro MerLion Pharmaceuticals GmbH N/A 2016-03-11 2022-03-11 Yes 2024-09-11 flibanserin 189352 Addyi Searchlight Pharma Inc. N/A 2018-02-27 2024-02-27 N/A 2026-02-27 florbetaben (18F) 193105 Neuraceq Isologic Innovative Radiopharmaceuticals Ltd. N/A 2017-02-22 2023-02-22 N/A 2025-02-22 follitropin delta 188743 Rekovelle Ferring Inc. N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc. N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc.

N/A 2019-07-30 2025-07-30 N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin Pharmaceutical Inc. N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc. N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd. N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc.

N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes 2022-01-05 guselkumab 200590 Tremfya Janssen Inc. N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc. N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 icatibant acetate 162918 Firazyr Takeda Canada Inc.

N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc. N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc. N/A 2021-05-26 2027-05-26 N/A 2029-05-26 idelalisib 172652 Zydelig Gilead Sciences Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 Besponsa Pfizer Canada Inc.

N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc. Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc. N/A 2017-12-07 2023-12-07 N/A 2025-12-07 iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc. N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc.

N/A 2016-12-23 2022-12-23 Yes 2025-06-23 ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc. N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc. N/A 2016-05-25 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda Canada Inc. N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc.

N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &. Lomb Incorporated N/A 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc. N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc. N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc. N/A 2017-11-01 2023-11-01 N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc.

N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc. N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc. N/A 2013-12-02 2019-12-02 N/A 2021-12-02 lixisenatide 193862 Adlyxine Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd. N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc.

N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu oxodotreotide 217184 Lutathera Advanced Accelerator Applications USA, Inc. N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc. N/A 2013-11-06 2019-11-06 Yes 2022-05-06 mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada Inc. N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc.

N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A 2025-09-05 modified vaccinia levitra (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight Therapeutics Inc. N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc. N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily B 195550 Trumenba Pfizer Canada Inc. N/A 2017-10-05 cheap levitra 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc.

N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc. N/A 2019-06-27 2025-06-27 N/A 2027-06-27 nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc. N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc. N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc. N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 Jetrea ThromboGenics N.V.

N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc. N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc. N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc.

N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin 192925 Ozanex Ferrer Internacional, S.A. N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc. Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V.

N/A 2019-06-07 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc. N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc. N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant hydrochloride 238175 Wakik Endo Ventures Ltd. N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc.

N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc. N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc. N/A 2018-10-26 2024-10-26 N/A 2026-10-26 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A 2027-11-01 ponatinib hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc.

N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc. N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc. N/A 2017-01-05 2023-01-05 Yes 2025-07-05 radium - 223 dichloride 161312 Xofigo Bayer Inc. N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc. N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomalevitra types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc.

N/A 2015-02-05 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc. N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc. N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 remdesivir 240551 Veklury Gilead Sciences Canada, Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 reslizumab 185873 Cinqair Teva Canada Limited N/A 2016-07-20 2022-07-20 Yes 2025-01-20 ribociclib (supplied as ribociclib succinate) 203884 Kisqali Novartis Pharmaceuticals Canada Inc.

N/A 2018-03-02 2024-03-02 N/A 2026-03-02 rifaximin 161256 Zaxine Salix Pharmaceuticals Inc. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 riociguat 162761 Adempas Bayer Inc. N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc. N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen Canada Inc. N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc.

N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc. N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide mesylate) 207115 Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc. N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc. N/A 2015-02-27 2021-02-27 Yes 2023-08-27 selexipag 182114 Uptravi Janssen Inc.

N/A 2016-01-20 2022-01-20 N/A 2024-01-20 semaglutide 202059 Ozempic Novo Nordisk Canada Inc. Rybelsus 2018-01-04 2024-01-04 N/A 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc. N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc. N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 Sovaldi Gilead Sciences Canada Inc.

HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd. N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck Canada Inc. N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc. N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC N/A 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc.

N/A 2014-05-29 2020-05-29 Yes 2022-11-29 tedizolid phosphate 173603 Sivextro Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc. N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc. N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc. N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc.

DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc. N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc. N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 Xeljanz Pfizer Canada Inc. N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc.

N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc. N/A 2021-04-15 2027-04-15 N/A 2029-04-15 trastuzumab emtansine 162414 Kadcyla Hoffmann-La Roche Limited N/A 2013-09-11 2019-09-11 N/A 2021-09-11 trifarotene 221945 Aklief Galderma Canada Inc. N/A 2019-11-25 2025-11-25 Yes 2028-05-25 tipiracil hydrochloride 205852 Lonsurf Taiho Pharma Canada Inc. N/A 2018-01-25 2024-01-25 N/A 2026-01-25 triheptanoin 242196 Dojolvi Uagenyx Pharmaceutical Inc. N/A 2021-02-15 2027-02-15 Yes 2029-08-15 tucatinib 235295 Tukysa Seattle Genetics Inc.

N/A 2020-06-05 2026-06-05 N/A 2028-06-05 turoctocog alfa 170796 Zonovate Novo Nordisk Canada Inc. N/A 2014-12-08 2020-12-08 Yes 2023-06-08 umeclidinium bromide 161585 Anoro Ellipta GlaxoSmithKline Inc. Incruse Ellipta 2013-12-23 2019-12-23 N/A 2021-12-23 upadacitinib 223734 Rinvoq AbbVie Corporation N/A 2019-12-23 2025-12-23 N/A 2027-12-23 varicella-zoster levitra glycoprotein E (gE) 200244 Shingrix GlaxoSmithKline Inc. N/A 2017-10-13 2023-10-13 N/A 2025-10-13 vedolizumab 169414 Entyvio Takeda Canada Inc. N/A 2015-01-29 2021-01-29 Yes 2023-07-29 velpatasvir 190521 Epclusa Gilead Sciences Canada Inc.

Vosevi 2016-07-11 2022-07-11 Yes 2025-01-11 venetoclax 190761 Venclexta AbbVie Corporation N/A 2016-09-30 2022-09-30 N/A 2024-09-30 vernakalant hydrochloride 190817 Brinavess Cipher Pharmaceuticals Inc. N/A 2017-03-13 2023-03-13 N/A 2025-03-13 vilanterol trifenatate 157301 Breo Ellipta GlaxoSmithKline Inc. Anoro ElliptaTrelegy Ellipta 2013-07-03 2019-07-03 Yes 2022-01-03 vilazodone hydrochloride 176820 Viibryd Allergan Inc. N/A 2015-07-16 2021-07-16 Yes 2024-01-16 vismodegib 154608 Erivedge Hoffmann-La Roche Ltd. N/A 2013-07-12 2019-07-12 N/A 2021-07-12 von willebrand factor (recombinant) (vonicog alfa) 213188 Vonvendi Takeda Canada Inc.

N/A 2019-01-10 2025-01-10 N/A 2027-01-10 vorapaxar sulfate 179320 Zontivity Toprol Acquisition LLC N/A 2016-05-13 2022-05-13 N/A 2024-05-13 voretigene neparvovec 233097 Luxturna Novartis Pharmaceuticals Canada Inc. N/A 2020-10-13 2026-10-13 Yes 2029-04-13 vortioxetine hydrobromide 159019 Trintellix Lundbeck Canada Inc. N/A 2014-10-22 2020-10-22 Yes 2023-04-22 voxilaprevir 202324 Vosevi Gilead Sciences Canada Inc. N/A 2017-08-16 2023-08-16 N/A 2025-08-16 zanubrutinib 242748 Brukinsa BeiGene Switzerland GmbH N/A 2021-03-01 2027-03-01 N/A 2029-03-01What is the Notice of Compliance (NOC) Data Extract?. The data extract is a series of compressed ASCII text files of the database.

The uncompressed size of the files is approximately 22.7 MB. In order to utilize the data, the file must be loaded into an existing database or information system. The typical user is most likely a third party claims adjudicator, provincial formulary, insurance company, etc. A casual user of this file must be familiar with database structure and capable of setting up queries. The "Read me" file contains the data structure required to download the zipped files.The NOC extract files have been updated.

They contain Health Canada authorization dates for all drugs dating back to 1994 that have received an NOC. All NOCs issued between 1991 and 1993 can be found in the NOC listings.Please note any Portable Document Format (PDF) files visible on the NOC database are not part of the data extracts.For more information, please go to the Read Me File.Data Extracts - Last updated. 2021-06-25 CopyrightFor information on copyright and who to contact, please visit the Notice of Compliance Online Database Terms and Conditions.The first WHO World Local Production Forum ended today after five days of discussions centered on promoting quality and sustainable local production to improve access to medicines and other health technologies.Delegates from over 100 countries, international partners, civil society groups, industry associations, and major investors joined WHO, WTO, UNIDO, UNICEF and UNCTAD to highlight the challenges facing local production and the steps required to address them, as well as the range of opportunities for the sector. Looking ahead, the Forum will provide a platform to drive forward efforts to support and enhance local production of health products in low- and middle-income countries. Forum conclusions, recommendations and next stepsIncreasing manufacturing capacity for global security - The erectile dysfunction treatment levitra has highlighted the importance of local manufacturing as a key component of levitra response by reducing reliance on global markets and imported products.

treatment production was a central theme at the Forum, as were the role of new technologies and generation of flexible manufacturing strategies to develop sustained production capacity in low- and middle-income countries. Technology transfer and licensing were seen as key to scaling up production. Sharing intellectual property and know-how will be essential, along with facilitation of voluntary licensing and effective technology transfer. It will also be vital to create a favourable environment for technology transfer. Key elements will include good governance.

A skilled workforce. Good access to market information and careful assessment of local capacity to receive and absorb the transferred technology.Governments’ role is key in creating an enabling political environment and a supportive business eco-system. Such efforts must be coordinated with relevant stakeholders at national, regional and global levels. National regulators and local manufacturers can drive quality-compliant local production and facilitate faster access to health technologies during levitras and beyond. To do that, they need continued training, support and resources.Low access to capital is a key limiting factor for local manufacturers in low- and middle-income countries.

The greater interest expressed by key development banks and other financial institutions towards investing in the sector indicates improvement in this area, whilst the need to develop strong investment cases, including demonstration of a long term economically viable business case, were highlighted as key components of successful manufacturing projects.A mechanism to stimulate industry engagement was recommended for strengthened collaboration with and among industry bodies with the aim of transferring priority technologies to low- and middle-income countries. A strategic advisory group should be established by WHO in collaboration with Member States and partners to address current and future global challenges and trends in local production and technology transfer.The next Forum will be held in The Netherlands as announced by Deputy Prime Minister and Minister of Health, Welfare and Sport, Hugo De Jonge. The Local Production Forum is now established as a long-term mechanism to promote dialogue and decision-making to strengthen local manufacturing capacity and move towards the shared goal of universal access to health technologies.On June 15, 2021, we, the Directors General of WHO, WIPO and the WTO, met in a spirit of cooperation and solidarity to map out further collaboration to tackle the erectile dysfunction treatment levitra and the pressing global challenges at the intersection of public health, intellectual property and trade. Acutely conscious of our shared responsibility to communities across the world as they confront a health crisis of unprecedented severity and scale, we pledged to bring the full extent of the expertise and resources of our respective institutions to bear in ending the erectile dysfunction treatment levitra and improving the health and well-being of all people, everywhere around the globe. We underscored our commitment to universal, equitable access to erectile dysfunction treatments, therapeutics, diagnostics, and other health technologies – a commitment anchored in the understanding that this is an urgent moral imperative in need of immediate practical action.

In this spirit, we agreed to build further on our long-standing commitment to WHO-WIPO-WTO Trilateral Cooperation that aims to support and assist all countries as they seek to assess and implement sustainable and integrated solutions to public health challenges. Within this existing cooperative framework, we agreed to enhance and focus our support in the context of the levitra through two specific initiatives.First, our three agencies will collaborate on the organization of practical, capacity-building workshops to enhance the flow of updated information on current developments in the levitra and responses to achieve equitable access to erectile dysfunction treatment health technologies. The aim of these workshops is to strengthen the capacity of policymakers and experts in member governments to address the levitra accordingly. The first workshop in the series will be a workshop on technology transfer and licensing, scheduled for September. The workshop will help our members update their knowledge and understanding of how intellectual property, know-how and technology transfer work in actuality.

This would be in the context of medical technologies and related products and services. This first workshop will be followed by others on related practical themes. Secondly, we will implement a joint platform for tripartite technical assistance to countries relating to their needs for erectile dysfunction treatment medical technologies, providing a one-stop shop that will make available the full range of expertise on access, IP and trade matters provided by our organizations, and other partners, in a coordinated and systematic manner. The platform for technical assistance will, in particular, support countries to assess and prioritize unmet needs for erectile dysfunction treatments, medicines and related technologies, and provide timely and tailored technical assistance in making full use of all available options to access treatments, medicines and technologies, including through coordination between members facing similar challenges to facilitate collective responses.These initiatives will also be underpinned by our joint efforts to collect and make accessible robust and inclusive data needed to guide an effective response to the erectile dysfunction treatment levitra. This will include a periodical update of the overview of erectile dysfunction treatment 19-related measures that are mapped in a key resource for trilateral cooperation, the WHO-WIPO-WTO publication 'Promoting Access to Medical Technologies and Innovation.

Intersections between public health, intellectual property and trade', published in 2020.BackgroundThe World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) have, since 2009, stepped up their cooperation and practical coordination on issues relating to public health, IP and trade. This trilateral cooperation is intended to enhance the empirical and factual information basis for policy makers and to support them in addressing public health in relation to IP and trade. It has entailed a series of practical technical assistance activities, at the national, regional and mulitilateral levels, a series of high-level Policy Symposia intended to track emerging issues and inform future policy, and the trilateral study, which provides a comprehensive overview of the full array of policy issues with bearing on innovation and access to medical technologies..

.